Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04979650 (ClinicalTrials.gov)	May 22, 2021	2/7/2021	Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis	Corticosteroid Pulse Therapy Effects on MRI Asymptomatic Gadolinium-enhancing Lesions Conversion to a Non-enhancing Black Hole With or Without Treatment in MS Clinic of Booalisina Hospital Sari 2021-2023	Multiple Sclerosis, Relapsing-Remitting;Magnetic Resonance Imaging;Methylprednisolone	Drug: Methylprednisolone succinate;Drug: Normal saline	Mazandaran University of Medical Sciences	NULL	Enrolling by invitation	18 Years	55 Years	All	104	Phase 2	Iran, Islamic Republic of
2	NCT01911377 (ClinicalTrials.gov)	October 2013	25/7/2013	Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS	The Efficacy of Botulinum Toxin Type A in the Treatment of Allodynic-Type Neuropathic Pain in People With Spinal Cord Injury or Multiple Sclerosis	Neuropathic Pain;Allodynia	Drug: Botulinum Toxin Type A;Drug: Normal Saline for Injection	University of Manitoba	Allergan	Terminated	18 Years	70 Years	Both	12	Phase 2	Canada
3	NCT01600716 (ClinicalTrials.gov)	June 13, 2012	15/5/2012	Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)		Urinary Incontinence;Multiple Sclerosis;Neurogenic Bladder	Biological: OnabotulinumtoxinA;Drug: Placebo (Normal Saline)	Allergan	NULL	Completed	18 Years	N/A	All	144	Phase 3	United States;Belgium;Canada;Czechia;France;Poland;Portugal;Russian Federation;Czech Republic
4	NCT01212094 (ClinicalTrials.gov)	September 2010	29/9/2010	Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)	Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)	Multiple Sclerosis	Drug: Rituximab;Other: normal saline	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Terminated	18 Years	65 Years	All	44	Phase 1/Phase 2	United States